Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aspivix's Carevix Cervical Stabilizer Gains FDA OK - Medical Product Outsourcing
OEM News

Aspivix’s Carevix Cervical Stabilizer Gains FDA OK

Atraumatic cervical stabilizer uses a gentle approach to reduce pain and bleeding for transcervical procedures.

Aspivix, a developer of gynecological technologies, has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its Carevix cervical stabilizer.
 
The Carevix atraumatic cervical stabilizer uses a gentle approach to reduce pain and bleeding for transcervical procedures like intrauterine device (IUD) insertions. The company’s ADVANCE study evaluated 100 women who underwent IUD insertion either with Carevix or a traditional cervical tenaculum: women reported “statistically significant results with up to 73% reduction of pain scores and 78% reduction of bleeding occurrences in favor of the Carevix device.”1


Carevix by Aspivix versus cervical tenaculum.
 
Mathieu Horras, CEO of Aspivix told the press: “With the 510(k) clearance of Carevix, a design-award winning device, we will provide our U.S. customers with an innovative and easy-to-use system that brings a gentler alternative to a century-old gynecological tool. Extensive research was incorporated into the development of Carevix so we know the unique and differentiating features it demonstrates with significant less pain and bleeding that has the potential to dramatically improve the IUD adoption and placement experience for millions of American women.”
 
Reference
1 Dr. Yaron, Michal. “Safety and efficacy of an innovative atraumatic cervical stabilizer for IUD insertion: Results from a randomized, single blind controlled study.” 30th World Congress on Controversies in Obstetrics, Gynecology, and Infertility (COGI), November 24-26, 2022, Amsterdam, The Netherlands. Oral Presentation.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters

Topics